Provigil (Modafinil) and Pregabalin Interaction: Safety, Mechanisms, and Clinical Guidance

Why This Combination Gets Flagged

Modafinil (brand name Provigil) and pregabalin (brand name Lyrica) produce opposing effects on central nervous system arousal. Modafinil increases wakefulness through dopaminergic and histaminergic pathways, while pregabalin depresses neuronal excitability by binding the alpha-2-delta subunit of voltage-gated calcium channels. That pharmacodynamic clash is the primary reason interaction checkers flag this pair.

The modafinil prescribing information identifies the drug as a moderate inducer of CYP3A4 and an inhibitor of CYP2C19 [1]. These hepatic enzyme effects matter for many co-prescribed medications. Pregabalin, though, is a notable exception. According to its FDA-approved label, pregabalin undergoes negligible hepatic metabolism, with approximately 98% of the absorbed dose recovered unchanged in urine [2]. This renal clearance profile means modafinil's CYP induction has no clinically meaningful effect on pregabalin blood levels.

The interaction is real but manageable. It does not require automatic dose changes or contraindication. It does require awareness.

Pharmacodynamic Mechanisms in Detail

The clinical concern centers on two opposing pharmacodynamic effects colliding in the same patient. Modafinil promotes wakefulness by inhibiting dopamine reuptake via the dopamine transporter (DAT) and by activating orexin/hypocretin neurons in the lateral hypothalamus [3]. Pregabalin, by contrast, reduces the release of glutamate, norepinephrine, and substance P at presynaptic terminals through its alpha-2-delta binding [4].

In practical terms, pregabalin's sedative properties may partially counteract modafinil's stimulant effect. A patient prescribed modafinil 200 mg each morning for narcolepsy who then starts pregabalin 150 mg twice daily for neuropathic pain could notice reduced wakefulness, increased daytime drowsiness, or cognitive blunting that was not present on modafinil alone.

The FDA label for pregabalin states: "Pregabalin may potentiate the effects of ethanol and lorazepam... patients should be advised that pregabalin may cause dizziness and somnolence" [2]. While modafinil is not ethanol or lorazepam, the underlying principle applies: any CNS-active drug paired with pregabalin can produce additive impairment in alertness and motor coordination.

There is also the question of additive rather than opposing effects. Both drugs can independently cause dizziness. Pregabalin produces dizziness in roughly 29% to 38% of patients at therapeutic doses in key trials, per pooled analyses reported in the label [2]. Modafinil causes dizziness in approximately 5% of patients [1]. The overlap raises fall risk, particularly in older adults.

Pharmacokinetic Profile: Why the Metabolic Interaction Is Minimal

Modafinil's enzyme effects are well documented. It induces CYP3A4 activity at steady state, which can reduce plasma concentrations of CYP3A4 substrates such as cyclosporine, midazolam, and ethinyl estradiol by 18% to 50% [1]. It also inhibits CYP2C19, raising levels of drugs like omeprazole and diazepam [5].

Pregabalin sidesteps this entirely. It has no protein binding. Zero. Its volume of distribution is approximately 0.5 L/kg, and it is not metabolized by any known cytochrome P450 isoenzyme [2]. The drug crosses into the CNS via the L-amino acid transporter system (system L), the same carrier used by leucine and other large neutral amino acids [6]. Renal clearance accounts for virtually all elimination, with a half-life of roughly 6.3 hours in adults with normal kidney function.

This pharmacokinetic independence means that adding modafinil will not raise or lower pregabalin blood levels. A 2004 pharmacokinetic study confirmed that pregabalin's clearance is directly proportional to creatinine clearance and unaffected by hepatic enzyme inducers or inhibitors [6]. The reverse is also true: pregabalin does not inhibit or induce any CYP enzyme, so it will not alter modafinil's metabolism.

One nuance deserves attention. Modafinil's induction of CYP3A4 affects its own metabolism (autoinduction), and steady-state levels of modafinil are approximately 20% lower after repeated dosing than after a single dose [1]. This autoinduction is unrelated to pregabalin, but patients and clinicians should know that modafinil's own pharmacokinetics shift over the first week of use.

Clinical Severity and DDI Database Ratings

Major drug interaction databases classify the modafinil-pregabalin pair as a moderate-severity interaction. The label does not list the combination as contraindicated, and no published case reports describe serious adverse outcomes specific to this pair.

For comparison, truly severe modafinil interactions involve drugs where CYP3A4 induction reduces a narrow-therapeutic-index drug to subtherapeutic levels. The FDA label warns that modafinil may decrease the effectiveness of steroidal contraceptives by roughly 18% [1]. That pharmacokinetic risk far exceeds the concern with pregabalin.

A 2012 review in the journal Clinical Pharmacokinetics noted that modafinil's CYP interactions "are of greatest concern with substrates of CYP3A4 that have narrow therapeutic windows, such as cyclosporine" [5]. Pregabalin, with no hepatic metabolism and a wide therapeutic window (doses range from 150 mg/day to 600 mg/day), falls outside that concern.

Still, the pharmacodynamic interaction means this pair warrants clinical monitoring rather than a casual "no interaction found" dismissal.

CNS Depression Risk: What the Evidence Shows

The additive CNS depression concern is most relevant in three clinical scenarios.

Titration phases. Both drugs require dose titration. Pregabalin is typically started at 75 mg twice daily and increased to 150 mg twice daily within one week [2]. Modafinil is initiated at 200 mg each morning, with some patients titrated to 400 mg [1]. Starting both simultaneously magnifies the risk of dizziness, ataxia, and somnolence during the period when side-effect profiles have not yet stabilized.

Patients with renal impairment. Pregabalin accumulates when creatinine clearance falls below 60 mL/min. In patients with creatinine clearance of 15 to 30 mL/min, the recommended maximum daily dose drops to 150 mg [2]. Higher-than-intended pregabalin exposure amplifies CNS depression and may overwhelm modafinil's wake-promoting effect.

Older adults. A 2019 analysis published in JAMA Internal Medicine found that pregabalin use in adults aged 65 and older was associated with a 1.5-fold increase in fall-related injuries compared with gabapentin [7]. Adding a second CNS-active drug raises that baseline risk.

The FDA's 2019 safety communication on gabapentinoids warned that "serious breathing difficulties can occur when gabapentinoids are combined with CNS depressants" [8]. Modafinil is not a typical CNS depressant, yet the broader message is clear: layering drugs that affect arousal, coordination, or respiratory drive demands careful clinical assessment.

Monitoring Recommendations

Prescribers managing patients on both modafinil and pregabalin should follow a structured monitoring approach.

Baseline. Document the Epworth Sleepiness Scale (ESS) score before adding either drug. The ESS provides a reproducible numeric benchmark. A score above 10 indicates excessive daytime sleepiness [9]. If pregabalin is added to an existing modafinil regimen, repeating the ESS at two and four weeks captures any erosion of wakefulness.

Weeks 1 to 4. Assess for new or worsened dizziness, somnolence, blurred vision, and peripheral edema (a pregabalin-specific effect occurring in roughly 6% of patients at 300 mg/day) [2]. Ask specifically about driving ability. The modafinil label advises that "the level of wakefulness in patients with excessive sleepiness treated with PROVIGIL may not return to normal," and patients should be counseled about operating vehicles [1].

Renal function. Check serum creatinine and estimated GFR at baseline and at least annually. Pregabalin dose must be reduced proportionally in renal impairment: 75 to 300 mg/day for CrCl 30 to 60 mL/min, 25 to 150 mg/day for CrCl 15 to 30 mL/min, and 25 to 75 mg/day for CrCl <15 mL/min [2].

Weight and edema. Pregabalin causes weight gain in 4% to 16% of clinical trial participants depending on dose [2]. Modafinil is weight-neutral to mildly anorexigenic. Track weight monthly during co-administration.

Dose Adjustment Guidance

Routine dose reductions of either drug are not required based solely on their co-administration. The lack of pharmacokinetic interaction means neither drug alters the other's blood levels.

Clinical dose adjustment may become necessary based on symptoms. If a patient reports that modafinil "stopped working" after pregabalin initiation, the first step is confirming adherence and checking for new causes of sedation (sleep apnea, anemia, hypothyroidism) before attributing the change to the interaction. If pregabalin-induced sedation is the most likely culprit, options include reducing the pregabalin dose to the lowest effective level, shifting the larger pregabalin dose to bedtime (e.g., 75 mg morning / 150 mg evening instead of equal twice-daily dosing), or switching to gabapentin, which has a shorter half-life and dose-dependent (saturable) absorption that may limit peak CNS exposure [10].

If modafinil's efficacy is insufficient at 200 mg despite optimization of the pregabalin schedule, the modafinil dose may be increased to 400 mg/day. The modafinil label notes that doses above 200 mg may not provide proportionally greater benefit, but individual responses vary [1].

Schedule IV Status and Abuse Potential Overlap

Both modafinil and pregabalin are classified as Schedule IV controlled substances by the U.S. Drug Enforcement Administration. Modafinil carries low but real abuse potential linked to its dopaminergic mechanism; a positron emission tomography study by Volkow et al. (2009) demonstrated that modafinil 400 mg blocked dopamine transporters in the nucleus accumbens in a pattern consistent with other wake-promoting stimulants [3].

Pregabalin's abuse liability is primarily linked to its anxiolytic and euphoric effects at supratherapeutic doses. A 2017 systematic review in CNS Drugs reported that pregabalin misuse prevalence in the general population ranges from 1.6% to 3.3%, rising to 8.5% to 26% among patients with a history of substance use disorder [11].

Prescribers should assess substance use history before co-prescribing two Schedule IV agents. State prescription drug monitoring programs (PDMPs) should be checked at initiation and periodically thereafter.

Patient Counseling Points

Patients receiving both medications should receive explicit guidance on five points.

First, timing. Take modafinil in the morning and the larger pregabalin dose at bedtime when sedation is acceptable. Second, driving. Do not drive or operate machinery until the combined side-effect profile has been stable for at least one week. Third, alcohol. Both drugs interact with ethanol. Combining all three multiplies CNS depression risk. Fourth, do not stop pregabalin abruptly. Discontinuation after prolonged use can cause withdrawal seizures, insomnia, and anxiety; the label recommends tapering over at least one week [2]. Fifth, report any new swelling of the hands or feet, unexplained weight gain above 3 kg, or unusual changes in mood to the prescribing clinician.

The American Academy of Neurology's 2021 practice guideline on narcolepsy management recommends reassessing all concomitant medications when a patient's sleepiness worsens despite adequate wake-promoting therapy [12]. Pregabalin should be high on that reassessment list given its sedation profile.